Remove BioTech Remove Life Science Remove Telehealth Remove Telemedicine
article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. Market forces drove acceleration in digital health, specifically telemedicine, which were sorely needed for several years. Connect with her at [link].

BioTech 107
article thumbnail

The Healthcare and Macro-Economic Impacts of Living with Endemic COVID – Listening to Fitch

Health Populi

While telehealth and virtual care stood up quickly in 2020, questions remain about how it will/can persist in terms of funding, regulation, and business models. We also expect innovation to come out of pharma and biotech labs, and who will pay for new-new therapies?

BioTech 270
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma’s Future Relevance Depends on Empathy, Messaging, Partnering, and Supporting Patients and Providers

Health Populi

This new work-flow for clinicians led to fast-adoption of virtual care platforms – telemedicine, tele-conferencing with patients via apps like Zoom and Skype along with commercially-built telehealth channels, and the prescription and use of remote health monitoring devices placed in patients’ homes.

article thumbnail

Value-Based Health Care Needs All Stakeholders at the Table – Especially the Patient

Health Populi

Speaking of design, this Summit was indeed well-designed by spotlighting pragmatic representatives from these various stakeholder groups.